The DOI matches its Crossref record.
The Outcome of 150 Babies Following the Treatment With Letrozole or Letrozole and Gonadotropins
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential for teratogenic effects of letrozole has been raised, with an abstract suggesting higher risk of congenital cardiac and bone malformations in newborns. 240”
From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [240]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target
Santen, R. J., Brodie, H. J., Simpson, E. R., Siiteri, P. K., & Brodie, A. M. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0016 · Cited by 447
Oktay, K., Hourvitz, A., Şahin, G., Öktem, Ö., Safro, B., Çil, A. P., & Bang, H. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0962 · Cited by 418
“A recent abstract questioned the safety of the use of aromatase inhibitors for ovulation induction (27).”
BackgroundAssessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline
Teede, H. J., Misso, M. L., Deeks, A. A., Moran, L. J., Stuckey, B. G. A., Wong, J. L. A., Norman, R. J., Costello, M. F., & Groups, O. B. O. T. G. D. (2011) · Medical Journal of Australia · doi:10.5694/mja11.10915 · Cited by 379
Tulandi, T., Martin, J., Al-Fadhli, R., Kabli, N., Forman, R., Hitkari, J., Librach, C., Greenblatt, E., & Casper, R. F. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.03.014 · Cited by 370
Ovulation induction in the management of anovulatory polycystic ovary syndrome
Balen, A. H. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.10.008 · Cited by 338
Blumenfeld, Z. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1044 · Cited by 274
“by on January 28, 2010 www.TheOncologist.com Downloaded from for locomotor and cardiac malformations [ 80 ].”
BackgroundAromatase Inhibitors for Ovulation Induction
Casper, R. F., & Mitwally, M. F. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1923 · Cited by 272
Kyrou, D., Kolibianakis, E. M., Venetis, C. A., Papanikolaou, E. G. E., Bontis, J. N., & Tarlatzis, B. C. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.12.077 · Cited by 239
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome
Franik, S., Eltrop, S., Kremer, J. A. M., Kiesel, L., & Farquhar, C. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010287.pub3 · Cited by 208
Mild ovarian stimulation for IVF
Verberg, M. F. G., Macklon, N., Nargund, G., Frydman, R., Devroey, P., Broekmans, F. J., & Fauser, B. C. J. M. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn056 · Cited by 193
“Recent data have raised concerns regarding possible teratogeneity of aromatase inhibitors (Biljan et al., 2005) and ovarian stimulation is currently an off-label use again marketer's advice.”
BackgroundPolycystic ovary syndrome throughout a woman’s life
Group of interest in Reproductive Endocrinology (GIER) of the Spanish Fertility Society (SEF), Bellver, J., Rodríguez-Tabernero, L., Robles, A., Muñoz, E., Martínez, F., Landeras, J., García-Velasco, J., Fontes, J., Álvarez, M., et al. (2018) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-017-1047-7 · Cited by 180
“A potential risk of teratogenic effects of letrozole was suggested in a preliminary report [80], but subsequent studies have discarded them [78].”
BackgroundRodgers, R. J., Reid, G., Koch, J., Deans, R., Ledger, W. J., Friedlander, M. L., Gilchrist, R. B., Walters, K. A., & Abbott, J. A. (2017) · Human Reproduction · doi:10.1093/humrep/dex027 · Cited by 146
Bosdou, J. K., Venetis, C. A., Kolibianakis, E. M., Toulis, K. A., Goulis, D. G., Zepiridis, L., & Tarlatzis, B. C. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr051 · Cited by 141
“Aromatase inhibitor use for ovarian stimulation has been associated with an increased incidence of congenital malformations (Biljan et al., 2005), although further published data seem to be reassuring (Tulandi et al.”
BackgroundWang, R., Kim, B. V., van Wely, M., JOHNSON, N. P., Costello, M., Zhang, H., Ng, E. H. Y., Legro, R. S., Bhattacharya, S., Norman, R. J., et al. (2017) · BMJ · doi:10.1136/bmj.j138 · Cited by 135
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome
Sharpe, A., Morley, L. C., Tang, T. H., Norman, R. J., & Balen, A. H. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013505 · Cited by 141
Aromatase inhibitors for subfertile women with polycystic ovary syndrome
Franik, S., Kremer, J. A. M., Nelen, W. L. D. M., & Farquhar, C. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010287.pub2 · Cited by 125
Costello, M., Misso, M. L., Balen, A. H., Boyle, J., Devoto, L., Garad, R. M., Hart, R. J., Johnson, L., Jordan, C., Legro, R. S., et al. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy021 · Cited by 128
“, 2014a,b) and concerns have been raised in an abstract on potential teratogenic effects (Biljan et al., 2005), which are as yet unconfirmed in peer-reviewed publications, yet this has sparked a series of warnings”
BackgroundSchoolcraft, W. B., Surrey, E. S., Minjarez, D. A., Stevens, J. M., & Gardner, D. K. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.02.013 · Cited by 103
Azim, A. A., Costantini-Ferrando, M. F., Lostritto, K., & Oktay, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0247 · Cited by 101
Casper, R. F., & Mitwally, M. F. (2011) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3182353d0f · Cited by 99
Ovulation induction in polycystic ovary syndrome
Tanbo, T. G., Mellembakken, J. R., Bjercke, S., Ring, E., Åbyholm, T., & Fedorcsák, P. (2018) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13395 · Cited by 98
Aromatase inhibitors for PCOS: a systematic review and meta-analysis
Misso, M. L., Wong, J. L. A., Teede, H. J., Hart, R. J., Rombauts, L. J. F., Melder, A., Norman, R. J., & Costello, M. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms003 · Cited by 96
“Initially, there was concern that the use of letrozole for infertility treatment may be associated with teratogenic effects (Biljan et al., 2005), but later publications did not find an association with fetal anomalies (Tulandi et al.”
BackgroundOvulation Induction in Polycystic Ovary Syndrome
Vause, T. D. R., Cheung, A. P., Cheung, A. P., Sierra, S., Claman, P., Graham, J., Guillemin, J.-A., Lapensée, L., Steward, S., Vause, T. D. R., et al. (2010) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)34504-2 · Cited by 97
Badawy, A., Shokeir, T. A., ALLAM, A. F., & Abdel‐Hady, H. (2008) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1080/00016340802638199 · Cited by 90
“(2005) suggested that the use of letrozole for infertility treatment might be associated with a higher risk of congenital cardiac and bone malformations in the newborns (7).”
BackgroundInfluentialYaralı́, H., Esinler, İ., Polat, M., Bozdağ, G., & Tıraş, B. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.04.057 · Cited by 86
The treatment of infertility in polycystic ovary syndrome: a brief update
Costello, M., Misso, M. L., Wong, J., Hart, R. J., Rombauts, L. J. F., Melder, A., Norman, R. J., & Teede, H. J. (2012) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2012.01448.x · Cited by 85
Fetal Safety of Letrozole and Clomiphene Citrate for Ovulation Induction
Forman, R., Gill, S., Moretti, M., Tulandi, T., Koren, G., & Casper, R. (2007) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32551-8 · Cited by 86
Comparison of different stimulation protocols used in in vitro fertilization: a review.
Shrestha, D., La, X., & Feng, H. L. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.04.09 · Cited by 83
Sharma, S., Ghosh, S., Singh, S., Chakravarty, A., Ganesh, A., Rajani, S., & Chakravarty, B. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108219 · Cited by 77
“The study presented by Biljan et al (2005) at ASRM meeting in which they compared 130 letrozole pregnancies with over 36,000 low risk spontaneous pregnancies, reported that letrozole might increase the risk of cardiac and bone anomalies in the newborns [6] however, the overall rate of major…”
BackgroundResultInfluentialDrugs in infertility and fetal safety
Elizur, S. E., & Tulandi, T. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.02.092 · Cited by 80
Badawy, A., Mosbah, A., & Shady, M. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.05.010 · Cited by 76
RetractedLetrozole for ovulation induction and controlled ovarian hyperstimulation
Pritts, E. A. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32833beebf · Cited by 76
Roque, M., Tostes, A. C. I., Valle, M., Sampaio, M. A. C., & Geber, S. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1096337 · Cited by 67
“with letrozole, either alone or in combination with gonadotropin [32].”
BackgroundAromatase inhibitors in ovarian stimulation
Casper, R. F. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.05.025 · Cited by 68
Strategies to reduce multiple pregnancies due to ovulation stimulation
Dickey, R. P. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.08.008 · Cited by 66
“The safety of LET is currently under review because of a possible association with congenital anomalies (80).”
BackgroundFouda, U. M., & Sayed, A. M. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-84 · Cited by 64
A historical perspective of aromatase inhibitors for ovulation induction
Casper, R. F., & Mitwally, M. F. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.10.008 · Cited by 64
Hashim, H. A., Shokeir, T. A., & Badawy, A. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.07.985 · Cited by 63
“Preliminary data (22) suggested an increased risk of congenital anomalies in letrozole-treated babies, whereas recent data from a retrospective trial (23) and a randomized study (24) contested these initial findings and supported its safety.”
ResultRetractedBadawy, A., Elnashar, A., & Totongy, M. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.013 · Cited by 63
“It suggested that the use of letrozole for infertility treatment might be associated with a higher risk of congenital cardiac malformations in the newborns (29).”
BackgroundRetractedFranik, S., Le, Q.-K., Kremer, J. A. M., Kiesel, L., & Farquhar, C. M. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010287.pub4 · Cited by 63
Mohsen, I. A., & Din, R. E. E. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2012.730569 · Cited by 59
“Despite the initial report of possibly increased congenital cardiac malformations [29], reassuring data were recently reported that show no such increase in the overall rates of malformations [30].”
BackgroundA brief update on the evidence supporting the treatment of infertility in polycystic ovary syndrome
Costello, M., Misso, M. L., Balen, A. H., Boyle, J. A., Devoto, L., Garad, R. M., Hart, R. J., Johnson, L., Jordan, C., Legro, R. S., et al. (2019) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13051 · Cited by 58
Aromatase inhibitors for female infertility: a systematic review of the literature
Polyzos, N. P., Tzioras, S., Badawy, A., Valachis, A., Dritsas, C., & Mauri, D. N. (2009) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2009.06.008 · Cited by 57
Løssl, K., Andersen, A. N., Loft, A. G., Freiesleben, N. L. C., Bangsbøll, S., & Andersen, C. Y. (2006) · Human Reproduction · doi:10.1093/humrep/del221 · Cited by 55
“This will be important to evaluate in future studies because the increased risk of locomotor and cardiac malformations has recently been reported following the use of letrozole from days 3 to 7 for ovulation induction (Biljan et al., 2005).”
BackgroundThe Use of Aromatase Inhibitors for Ovulation Induction and Superovulation
Pavone, M. E., & Bulun, S. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1328 · Cited by 57
Gregoriou, O., Vlahos, N., Konidaris, S., Papadias, K., Botsis, D. S., & Creatsas, G. K. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.06.099 · Cited by 54
Tsiami, A. P., Goulis, D. G., Sotiriadis, A., & Kolibianakis, E. M. (2021) · HORMONES · doi:10.1007/s42000-021-00289-z · Cited by 54
Current evidence supporting "letrozole" for ovulation induction
Kar, S. (2013) · Journal of Human Reproductive Sciences · doi:10.4103/0974-1208.117166 · Cited by 56
“Marinko Biljan presented an oral abstract at ASRM of 150 babies born after letrozole use.[3] This was compared with 36,000 spontaneous conceptions of the normal population.”
ResultInfluentialLøssl, K., Andersen, C. Y., Loft, A. G., Freiesleben, N. L. C., Bangsbøll, S., & Andersen, A. N. (2008) · Human Reproduction · doi:10.1093/humrep/den131 · Cited by 53
“The safety of aromatase inhibitors in assisted reproduction has been raised, as a higher prevalence of locomotor abnormalities was found among 150 children born after the use of letrozole for ovulation induction when compared to 36 000 children born after spontaneous conception in a non-infertile, low risk population…”
BackgroundThe effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women
Checa, M. Á., Corchado, A. R., Cuadri, M. E. S., González-Comadran, M., Brassesco, M., & Carreras, R. (2012) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2012.02.020 · Cited by 52
Tatsumi, T., Jwa, S. C., Kuwahara, A., et al. (2016) · Human Reproduction · doi:10.1093/humrep/dew280 · Cited by 52
“Letrozole use was associated with increased risks of congenital cardiac and musculoskeletal abnormalities in neonates according to a conference presentation reported in 2005 (Biljan et al., 2005; Novartis Pharmaceuticals Canada Inc., 2005; Tulandi et al., 2006), following which its manufacturers, Novartis Pharma, issu…”
BackgroundResultInfluentialInfertility and pregnancy after breast cancer: Current knowledge and future perspectives
Mastro, L. D., Catzeddu, T., & Venturini, M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.05.004 · Cited by 47
Potential role of aromatase inhibitors in the treatment of endometriosis
Hashim, H. A. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s34684 · Cited by 46
“A poorly done abstract published by the ASRM in 2005, 73 which never resulted in a paper, raised concerns of increased cardiac and bone malformations in new-borns of letrozole-treated pregnancies compared with controls.”
New advances in ovulation induction
Kafy, S., & Tulandi, T. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3280c60c9a · Cited by 47
Cost-effectiveness of aromatase inhibitor co-treatment for controlled ovarian stimulation
Bedaiwy, M. A., Forman, R., Mousa, N. A., Inany, H., & Casper, R. F. (2006) · Human Reproduction · doi:10.1093/humrep/del273 · Cited by 46
Lee, V. C. Y., Chan, C. C. W., Ng, E. H. Y., Yeung, W. S. B., & Ho, P. C. (2011) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2011.05.012 · Cited by 44
“One major concern of using letrozole in ovulation induction or ovarian stimulation is its possible teratogenicity (Biljan et al. 2005).”
BackgroundRisk of foetal harm with letrozole use in fertility treatment: a systematic review and meta-analysis
Pundir, J., Achilli, C., Bhide, P., Sabatini, L., Legro, R. S., Rombauts, L. J. F., Teede, H. J., Coomarasamy, A., Zamora, J., & Thangaratinam, S. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa055 · Cited by 45
Aromatase inhibitors for ovulation induction and ovarian stimulation
Lee, V. C. Y., & Ledger, W. J. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04006.x · Cited by 42
Hashim, H. A., RAKHAWY, M. E., & Elaal, I. A. (2011) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2011.01346.x · Cited by 43
“Preliminary data (25) suggested an increased risk of congenital anomalies in letrozole-treated babies, whereas recent data from a retrospective trial (26) and a randomized trial (27) have contested these initial findings and supported its safety.”
ResultBülow, N. S., Skouby, S. O., Warzecha, A. K., Udengaard, H., Andersen, C. Y., Holt, M. D., Grøndahl, M. L., Andersen, A. N., Sopa, N., Englund, A. L. M., et al. (2021) · Human Reproduction · doi:10.1093/humrep/deab249 · Cited by 40
Use of aromatase inhibitors in practice of gynecology
Usluoğullari, B., Duvan, C. Z., & Usluoğulları, C. A. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0131-9 · Cited by 40
“7 years) [63].”
Hashim, H. A., Foda, O., & Ghayaty, E. (2015) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12673 · Cited by 37
“A potential safety concern regarding the newborns was initially raised (40); however, recent data have supported its safety (41,42).”
ResultPrinciples of Human Teratology: Drug Chemical and Infectious Exposure
Wilson, R. D., Wilson, R. D., Johnson, J.-A., et al. (2007) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32668-8 · Cited by 36
Ebrahimi, M., Akbari-Asbagh, F., & Ghalandar-Attar, M. (2017) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.29252/ijrm.15.2.101 · Cited by 35
“An Initial study has suggested an increase in cardiac, musculoskeletal system malformations and low birth weight in offspring of mothers who conceived with letrozole (26).”
BackgroundManagement of anovulatory infertility
Li, R., & Ng, E. H. Y. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2012.05.004 · Cited by 33
Artini, P. G., Obino, M. E. R., Sergiampietri, C., Pinelli, S., Papini, F., Casarosa, E., & Cela, V. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1431122 · Cited by 35
Bülow, N. S., Holt, M. D., Skouby, S. O., Petersen, K. B., Englund, A. L. M., Pinborg, A. B., & Macklon, N. S. (2021) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2021.12.006 · Cited by 34
The use of aromatase inhibitors in in vitro fertilization
García-Velasco, J. A. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.09.042 · Cited by 32
Hashim, H. A., Mashaly, A. E.-M., & Badawy, A. (2010) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1566-2 · Cited by 32
“[24] suggested an increased risk of congenital anomalies in letrozole treated babies, whereas recent data from retrospective and prospective trials [25, 26] have contested these initial Wndings and supported the safety of letrozole compared to traditional ovulation induction treatment.”
ResultRetractedDehbashi, S., Dehbashi, S., Kazerooni, T., Robati, M., Alborzi, S., & Shadman, A. (2009) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 32
Costello, M., Garad, R. M., Hart, R. J., Homer, H. A., Johnson, L., Jordan, C., Mocanu, E. V., Qiao, J., Rombauts, L. J. F., Teede, H. J., et al. (2019) · Medical Sciences · doi:10.3390/medsci7090095 · Cited by 32
“Initially, there were concerns regarding the potential teratogenic effect of letrozole for infertility treatment [22] but a recent review of the published literature did not find an increased risk of foetal anomalies with letrozole [17].”
BackgroundThe Clinical Manifestations of Polycystic Ovary Syndrome (PCOS) and The Treatment Options
Karkera, S., Agard, E., & Sankova, L. (2023) · European Journal of Biology and Medical Science Research · doi:10.37745/ejbmsr.2013/vol11n15791 · Cited by 35
Liu, A., Zheng, C., Lang, J., & Chen, W. (2014) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.12393 · Cited by 31
Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology
Racca, A., Drakopoulos, P., Neves, A. R., & Polyzos, N. P. (2020) · Drugs · doi:10.1007/s40265-020-01324-w · Cited by 33
Nakasuji, T., Kawai, K., Ishikawa, T., et al. (2019) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12263 · Cited by 30
Ovulation Induction in Polycystic Ovary Syndrome
Vause, T. D. R., Cheung, A. P., Sierra, S., Claman, P., Graham, J., Guillemin, J., Lapensée, L., Steward, S., Vause, T. D. R., & Wong, B. C.-M. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2010.07.001 · Cited by 28
“These findings reported a higher incidence of both cardiac and bone abnormalities in the letrozole group [67].”
BackgroundAromatase inhibitors for subfertile women with polycystic ovary syndrome
Franik, S., Kremer, J. A. M., Nelen, W. L. D. M., et al. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010287 · Cited by 30
Potential of Aromatase Inhibitors for Ovulation and Superovulation Induction in Infertile Women
Mitwally, M. F., & Casper, R. F. (2006) · Drugs · doi:10.2165/00003495-200666170-00001 · Cited by 29
Ovulation triggers in anovulatory women undergoing ovulation induction
George, K., Nair, R., & Tharyan, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006900.pub2 · Cited by 28
Shapira, M., Orvieto, R., Lebovitz, O., Nahum, R., Aizer, A., Segev-Zahav, A., & Haas, J. (2020) · Journal of Ovarian Research · doi:10.1186/s13048-020-00666-z · Cited by 27
Hashim, H. A. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-012-2261-2 · Cited by 28
“According to an abstract published by the American Society for Reproductive Medicine (ASRM) in 2005 [61], the use of letrozole for ovulation induction has been discouraged, since there was a signiWcant increase in congenital cardiac and bone malformations in newborns in letrozoletreated pregnancies compared with contr…”
Treatment Strategies for the Infertile Polycystic Ovary Syndrome Patient
Tannus, S., Burke, Y. Z., & Kol, S. (2015) · Women s Health · doi:10.2217/whe.15.40 · Cited by 31
Yu, Q., Hu, S., Wang, Y., et al. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0461-3 · Cited by 27
Yland, J. J., Chiu, Y., Rinaudo, P. F., Hsu, J., Hernán, M. Á., & Hernández–Dı́az, S. (2022) · Human Reproduction · doi:10.1093/humrep/deac005 · Cited by 26
ART: iatrogenic multiple pregnancy?
Verberg, M. F. G., Macklon, N., Heijnen, E., & Fauser, B. C. J. M. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.09.011 · Cited by 22
Malloch, L., & Rhoton-Vlasak, A. S. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.08.040 · Cited by 22
Role of androgens in the treatment of patients with low ovarian response
Feigenberg, T., Simon, A., Ben‐Meir, A., Gielchinsky, Y., & Laufer, N. (2009) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2009.09.012 · Cited by 21
“Recently, an abstract was presented during a meeting of the American Society for Reproductive Medicine (ASRM) (Biljan et al., 2005), raising the concern that the use of letrozole for infertility treatment might be associated with a higher risk of congenital cardiac and bone malformations in newborns.”
BackgroundElassar, A. A., Engmann, L., NULSEN, J. C., & Benadiva, C. A. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.03.103 · Cited by 19
Therapeutic options in the polycystic ovary syndrome
Bhathena, R. K. (2007) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443610601113797 · Cited by 18
“The possible teratogenicity of letrozole needs to be carefully evaluated (Biljan et al. 2005).”
BackgroundPhenotypic and pharmacogenetic aspects of ovulation induction in WHO II anovulatory women
Overbeek, A., & Lambalk, C. B. (2009) · Gynecological Endocrinology · doi:10.1080/09513590802571118 · Cited by 18
“Nevertheless, in an abstract presentation on the 2005 annual ASRM meeting, the authors reported an increased incidence in cardiac and locomotor malformations in the letrozole group [43].”
BackgroundSene, A. A., Ghorbani, S., & Ashrafi, M. (2018) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13644 · Cited by 17
“letrozole compared with 36 005 newborns from spontaneous pregnancies, which resulted in the prohibition of letrozole use to induce ovulation in many countries.(6) However, there were significant methodological errors in this study.”
BackgroundResultIs the use of letrozole to induce ovulation teratogenic?
Gill, S. K., Moretti, M. E., & Koren, G. (2008) · PubMed Central · Cited by 20
Ben‐Haroush, A., Farhi, J., Ben‐Aharon, I., et al. (2011) · PubMed · Cited by 16
Lambertini, M., Pescio, M. C., Viglietti, G., Goldrat, O., Mastro, L. D., Anserini, P., & Demeestere, I. (2016) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2017.1270760 · Cited by 16
“increased risk of congenital cardiac and musculoskeletal anomalies in the newborns [52]; hence, its manufacturer issued a warning to physicians to stop using letrozole for”
BackgroundEffects of a non-steroidal aromatase inhibitor on ovarian function in cattle
Yapura, J., Mapletoft, R. J., Singh, J. K., Pierson, R. A., Naile, J. E., Giesy, J. P., Chang, H., Higley, E. B., Hecker, M., & Adams, G. P. (2011) · Reproduction Fertility and Development · doi:10.1071/rd11239 · Cited by 16
“[133].”
The Risk of Congenital Anomalies by Fertility Treatment Modality
Chung, E. H., Harris, B. S. H., Muasher, S. J., et al. (2021) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000855 · Cited by 15
“In 2005, one retrospective analysis (N = 150) raised concerns for increased incidence of cardiovascular and skeletal anomalies in letrozole-conceived pregnancies compared with natural pregnancies.(75) Since then, numerous concerns have been voiced regarding the study's methodology.”
BackgroundOvulation triggers in anovulatory women undergoing ovulation induction
George, K., Kamath, M. S., Nair, R., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006900.pub3 · Cited by 14
Fatum, M., McVeigh, E., & Child, T. J. (2013) · Human Fertility · doi:10.3109/14647273.2013.800650 · Cited by 14
“A small study presented as an Abstract to the American Society for Reproductive Medicine meeting in 2005 suggested that Letrozole could cause serious foetal anomalies (Biljan et al., 2005).”
BackgroundNo. 362-Ovulation Induction in Polycystic Ovary Syndrome
Smithson, D. S., Vause, T. D. R., & Cheung, A. P. (2018) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2017.12.004 · Cited by 16
Fouda, U. M., & Sayed, A. M. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2011.579661 · Cited by 13
Metadata
- Authors
- Biljan, M. M., Hemmings, R., & Brassard, N.
- Affiliations
- St Mary's Hospital Centre (CA)
- ORCID
- Hemmings, R.
- Venue
- Fertility and Sterility
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 84
- Pages
- S95
- ISSN
- 0015-0282 (ISSN-L)
- OpenAlex
- W2115337926
- Cited by
- 206
- References
- 0
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 5 · 2022: 12 · 2021: 7 · 2020: 8 · 2019: 9 · 2018: 9 · 2017: 8 · 2016: 4 · 2015: 11 · 2014: 10 · 2013: 6 · 2012: 17
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Fertility and Sterility (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Assisted Reproductive Technology and Twin Pregnancy
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- letrozole, gonadotropins, ovulation induction, aromatase inhibitors, pregnancy outcomes, infertility treatment, assisted reproduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
